Holen Sie sich die Stockscreener-App
3.42
1.18%
0.04
Schlusskurs vom Vortag:
$3.38
Offen:
$3.34
24-Stunden-Volumen:
127.30K
Relative Volume:
0.11
Marktkapitalisierung:
$254.35M
Einnahmen:
$6.96M
Nettoeinkommen (Verlust:
$-46.51M
KGV:
-19.93
EPS:
-0.1716
Netto-Cashflow:
$-37.99M
1W Leistung:
-12.31%
1M Leistung:
-20.65%
6M Leistung:
+23.91%
1J Leistung:
-77.68%
1-Tages-Spanne:
$3.28
$3.47
1-Wochen-Bereich:
$3.28
$3.93
52-Wochen-Spanne:
$1.60
$16.55
Perspective Therapeutics Inc Stock (CATX) Company Profile
Firmenname
Perspective Therapeutics Inc
Sektor
Branche
Telefon
509-375-1202
Adresse
350 Hills Street, Suite 106, Richland
Vergleichen Sie CATX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.425 | 274.03M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
132.24 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.76 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
388.38 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.44 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
82.11 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-01 | Eingeleitet | Wedbush | Outperform |
| 2024-09-25 | Eingeleitet | Truist | Buy |
| 2024-07-25 | Eingeleitet | BofA Securities | Buy |
| 2024-05-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Perspective Therapeutics Reports Promising Study Results at ASCO - MSN
Does Perspective Therapeutics Inc. fit your quant trading modelPortfolio Risk Summary & Real-Time Chart Pattern Alerts - Newser
Volume spikes in Perspective Therapeutics Inc. stock – what they meanDividend Hike & Safe Capital Growth Stock Tips - Newser
What technical models suggest about Perspective Therapeutics Inc.’s comebackPortfolio Update Report & High Yield Stock Recommendations - Newser
How Perspective Therapeutics Inc. stock performs during market volatilityCPI Data & Stock Market Timing Techniques - Newser
Can Perspective Therapeutics Inc. hit a new high this monthCEO Change & Free Community Consensus Stock Picks - Newser
How to read the order book for Perspective Therapeutics Inc.July 2025 Weekly Recap & Reliable Intraday Trade Plans - Newser
Perspective Therapeutics price target raised to $16 from $15 at RBC Capital - MSN
Short Interest Drops in Perspective Therapeutics Inc. After RallyMarket Movers & Target Return Focused Stock Picks - sundaytimes.kr
Perspective Therapeutics Inc. Could See a Relief Rally From SupportMarket Risk Summary & Safe Swing Trade Setups - newsimpact.co.kr
Perspective Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Perspective Therapeutics Posts Q2 2025 Earnings, Highlights Clinical Progress and Financial Stability - AInvest
Perspective Therapeutics Reports Q2 2025 Progress and Financials - TipRanks
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $14 - 富途牛牛
Oppenheimer lowers Perspective Therapeutics stock price target to $14 - Investing.com India
Gain Therapeutics, Inc. shares rise 3.27% intraday after Perspective Therapeutics presented positive [212Pb]VMT-α-NET study update at ASCO Annual Meeting. - AInvest
Perspective Therapeutics reports Q2 EPS (29c), consensus (29c) - TipRanks
Perspective Therapeutics: Navigating the Theranostics Frontier with Precision and Purpose - AInvest
Perspective Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Perspective Therapeutics Q2 Loss: $21.5M, Aligns with ForecastNews and Statistics - IndexBox
Perspective Therapeutics Reports Q2 Loss - Mitrade
Perspective Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Perspective Therapeutics Inc (CATX) Q2 2025 Earnings: EPS Loss o - GuruFocus
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2025 Results - The Manila Times
CATX 8-K: Q2 2025 results released; corporate deck updated - Stock Titan
Cancer Drug Developer Perspective Sees Treatment Success: 4 of 7 Patients Respond in Phase 1/2a Trial - Stock Titan
What to do if you’re stuck in Perspective Therapeutics Inc.2025 Volume Leaders & AI Powered Trade Plan Recommendations - Newser
Perspective Therapeutics Q2 2025 Earnings Preview - MSN
Perspective Therapeutics Q2 Earnings Preview: Analysts Expect Losses and Revenue Decline - AInvest
Technical Models Suggest Perspective Therapeutics Inc. May Rebound SoonFree Group Entry - beatles.ru
What makes Perspective Therapeutics Inc. stock price move sharplyFree Trend Analysis for Safer Trades - Newser
Multi factor analysis applied to Perspective Therapeutics Inc.Free Value Investing Picks With Stability - Newser
Perspective Therapeutics (CATX) Projected to Post Earnings on Wednesday - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Ranking Perspective Therapeutics Inc. among high performing stocks via toolsFree Risk Controlled Short Term Trade Plans - Newser
Perspective Therapeutics, Inc. shares rise 3.09% after-hours following a corporate update on clinical progress and strategic positioning. - AInvest
Published on: 2025-08-04 12:18:12 - Jammu Links News
When is Perspective Therapeutics Inc. stock expected to show significant growthInvest smarter with expert stock recommendations - Jammu Links News
Why is Perspective Therapeutics Inc. stock attracting strong analyst attentionConsistent triple returns - Jammu Links News
What are the technical indicators suggesting about Perspective Therapeutics Inc.Unlock your portfolio’s hidden potential - Jammu Links News
How does Perspective Therapeutics Inc. generate profit in a changing economyBuild wealth steadily with proven methods - Jammu Links News
What are the latest earnings results for Perspective Therapeutics Inc.Unlock rapid growth potential in your portfolio - Jammu Links News
How many analysts rate Perspective Therapeutics Inc. as a “Buy”Build a strong portfolio for long-term success - Jammu Links News
Perspective Therapeutics: Giving Us Some Valuable Perspective On Alpha Emitter Therapy - Seeking Alpha
Perspective Therapeutics (NYSE:CATX) vs. Motus GI (NASDAQ:MOTS) Critical Contrast - Defense World
Perspective Therapeutics Updates Radiopharmaceutical Platform Presentation - TipRanks
Live market analysis of Perspective Therapeutics Inc.Predictive AI Engine for Smart Investing - Newser
Applying chart zones and confluence areas to Perspective Therapeutics Inc.Short-Term AI-Based Stock Price Forecast - Newser
When is the best time to exit Perspective Therapeutics Inc.Smart Trade Mapping with Entry Details - Newser
How strong is Perspective Therapeutics Inc. company’s balance sheetTop Growth Tips For Consistent Profits - jammulinksnews.com
Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.03%
0.82%
Kapitalisierung:
|
Volumen (24h):